Egrantil - instructions for use, analogs, testimonials and release forms (capsules or tablets 30 mg, 60 mg and 90 mg retard, injections) of a drug for the treatment of hypertension in adults, children and in pregnancy

In this article, you can read the instructions for using the drug Ebrantil. There are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors specialists on the use of Ebrantil in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Ebrantil in the presence of existing structural analogues. Use for the treatment of hypertension and pressure decrease inadults, children, as well as during pregnancy and lactation.

Ebrantil antihypertensive drug. Alfa1-adrenoblocker. Ebrantil blocks postsynaptic alpha 1-adrenergic receptors, thereby reducing peripheral resistance. In addition, Ebrantil regulates the central mechanism of maintaining vascular tone and has a weak beta-adrenergic blocking effect. Heart rate, cardiac output when it is administered does not change. Low cardiac output may be increased by decreasing vascular resistance. Orthostatic phenomena, as a rule, Ebrantil does not cause. Ebrantil blocks vasoconstriction caused by alpha2-adrenoreceptors, and does not cause reflex tachycardia due to vasodilation.

Ebrantil balancedly reduces systolic and diastolic blood pressure, reducing peripheral resistance and does not cause reflex tachycardia.

Urapidil (the active substance of the drug Ebrantil) reduces pre- and postnagruzku on the heart, increases the efficiency of cardiac contraction, thus, in the absence of arrhythmia, the drug increases the reduced minute volume of the heart.

Ebrantil has central and peripheral mechanisms of action.Primarily blocks peripheral postsynaptic alpha 1-adrenergic receptors, thus, the drug blocks the vasoconstrictive effect of catecholamines. In the central nervous system, urapidil affects the activity of the vasomotor center, which is manifested in preventing reflex increase (or decrease) in the tone of the sympathetic nervous system.

Urapidil does not affect the parameters of carbohydrate metabolism, the exchange of uric acid and does not cause fluid retention in the body.

Pharmacokinetics

Ebrantil penetrates through the blood-brain and placental barriers. 50-70% of urapidil and its metabolites (15% in the form of an active drug) is excreted by the kidneys, the rest is excreted through the intestines in the form of metabolites (mainly in the form of inactive p-hydroxylated urapidil).

Indications

• hypertensive crisis;
• refractory arterial hypertension;
• severe degree of arterial hypertension;
• controlled arterial hypotension during and / or after surgery.

Forms of release

Capsules of prolonged action of 30 mg, 60 mg and 90 mg retard (sometimes mistakenly called tablets).

Solution for intravenous administration 5 mg / ml (injections in ampoules for injection).

Instructions for use and dosage

Ebrantil is injected intravenously by jet or by prolonged infusion (dropper) (the patient should be in a prone position).

With hypertensive crisis, severe degree of hypertension, refractory hypertension, the drug is administered at a dose of 10-50 mg IV slowly under the control of blood pressure. Reduction of blood pressure is expected within 5 minutes after administration. Depending on the therapeutic effect, the repeated administration of the drug Ebrantil is possible.

In / in drip or continuous infusion is carried out using a perfusion pump. The maintenance dose is an average of 9 mg / h, i.e. 250 mg of the drug Ebrantil (10 amp 5 ml or 5 amp 10 ml) in 500 ml solution for infusion (1 mg = 44 drops = 2.2 ml). The maximum allowable ratio is 4 mg of the drug Ebrantil per 1 ml of solution for infusion. The recommended maximum initial speed is 2 mg / min. The rate of drip administration depends on the indices of the patient's blood pressure.

A drip infusion solution for maintaining blood pressure is prepared as follows: 250 mg of the preparation (10 ampoules of 5 ml or 5 ampules of 10 ml) are added to 500 ml of the infusion solution, for example saline, 5% or 10% Dextrose solution (glucose).

If a perfusion pump is used to administer the maintenance dose, 100 mg of the drug (4 ampoules of 5 ml or 2 10 ml ampoules) are injected into the syringe of the perfusion pump and diluted to 50 ml with saline, 5% or 10% dextrose (glucose) solution.

For controlled (controlled) reduction in blood pressure during its increase during and / or after surgery, Ehrrantil is administered iv in a dose of 25 mg. Reduction of blood pressure is expected within 2 minutes after administration. Then, stabilize the blood pressure with infusion (the initial dose of up to 6 mg in 1-2 minutes, then reduce the dose).

If this does not happen, i. E. BP does not change, then after 2 minutes, repeat intravenous injection of the drug Ebrantil in a dose of 25 mg. Reduction of blood pressure is expected within 2 minutes after administration. Then, stabilize the blood pressure with infusion (the initial dose of up to 6 mg in 1-2 minutes, then reduce the dose).

If this does not happen, i. E. The blood pressure does not change, then after 2 minutes a slow intravenous injection of the drug Ebrantil in a dose of 50 mg is performed. Blood pressure decreases after 2 minutes. Then, stabilize the blood pressure with infusion (the initial dose of up to 6 mg in 1-2 minutes, then reduce the dose).

Continuous infusion using a perfusion pump or drip infusion is used to maintain blood pressure at the level achieved by IV.

If previously used other antihypertensives, then Ebrantil, can be administered only after a period of time, sufficient to affect the previously introduced drug (s). The dose of Ebrantil should be adjusted accordingly.

The administration of the drug can be single or multiple. Injection administration of the drug can be combined with subsequent drip infusion. Parenteral therapy can be repeated with a new increase in blood pressure.

Side effect

• palpitation;
• tachycardia;
• bradycardia;
• a feeling of constriction in the chest;
• dyspnea;
• arrhythmias;
• nausea, vomiting;
• thrombocytopenia;
• dizziness;
• headache;
• fatigue;
• feeling of anxiety;
• proteinuria;
• nephropathy;
• nephrotic syndrome;
• increased sweating;
• itching;
• hyperemia.

Contraindications

• aortic stenosis;
• open bots of ducts;
• children under 18 years of age (efficacy and safety not established);
• pregnancy (efficacy and safety not established);
• lactation period (efficacy and safety not established);
• hypersensitivity to the drug.

Application in pregnancy and lactation

The drug is contraindicated for use in pregnancy and during lactation, tk. effectiveness and safety of its use in these periods are not established.

special instructions

Possible simultaneous use with other internal antihypertensive agents.

Drug Interactions

The hypotensive effect of Ehrrantil can be enhanced by joint admission with alpha-adrenoblockers or other antihypertensive agents, as well as hypovolemia (nausea, vomiting) and with ethanol (alcohol).

Analogues of the drug Ebrantil

The drug does not have structural analogs for the active substance.

Analogues for the pharmacological group (alpha-adrenoblockers):

• Alfuzosin;
• Alfuzosin;
• Artesine;
• Butyroxane;
• Hyperprost;
• Dalfaz;
• Ditamin;
• Doxazosin;
• Zooxon;
• Yohimbine hydrochloride;
• Camyrin;
• Cardura;
• Kornam;
• Nilogrin;
• Nicergoline;
• Omnik;
• Omsulosin;
• Pyrroxane;
• Polipressin;
• Prazosin;
• Propoxane;
• Proflosin;
• Revocarin;
• Redergin;
• Sermion;
• Setegis;
• Sonizine;
• Tamsulosin;
• Terazosin;
• Tonicardin;
• Tulosin;
• Urocardia;
• Urorek;
• Focussin;
• Heitrin.

Similar medicines:

Other medicines: